Endometrial adenocarcinoma following the conservative treatment of an atypical polypoid adenomyoma

1998 ◽  
Vol 3 (6) ◽  
pp. 400-402 ◽  
Author(s):  
H. Tashiro ◽  
H. Katabuchi ◽  
Y. Fukumatsu ◽  
N. Tanaka ◽  
K. Matsuura ◽  
...  
Keyword(s):  
Conservative Treatment ◽  
Endometrial Adenocarcinoma ◽  
Atypical Polypoid Adenomyoma

Coexistent atypical polypoid adenomyoma and endometrial adenocarcinoma

1995 ◽  
Vol 26 (5) ◽  
pp. 574-576 ◽  
Author(s):  
Khush R Mittal ◽  
Xiao C Peng ◽  
Robert C Wallach ◽  
Rita I Demopoulos
Keyword(s):  
Endometrial Adenocarcinoma ◽  
Atypical Polypoid Adenomyoma

Two Cases of Endometrial Adenocarcinoma Arising from Atypical Polypoid Adenomyoma

1998 ◽  
Vol 71 (1) ◽  
pp. 141-144 ◽  
Author(s):  
Toru Sugiyama ◽  
Shunichiro Ohta ◽  
Takashi Nishida ◽  
Naofumi Okura ◽  
Kiwako Tanabe ◽  
...  
Keyword(s):  
Endometrial Adenocarcinoma ◽  
Atypical Polypoid Adenomyoma

Peritoneal Keratin Granulomatosis Is a Clinical and Radiological Mimicker of Endometrial Adenocarcinoma With Peritoneal Involvement

2019 ◽  
Vol 27 (7) ◽  
pp. 757-759
Author(s):  
Jahg Wong ◽  
Simon F. Roy ◽  
François Gougeon
Keyword(s):  
Endometrial Adenocarcinoma ◽  
International Federation ◽  
Endometrioid Adenocarcinoma ◽  
Advanced Stage ◽  
Rare Tumor ◽  
Diagnostic Pitfall ◽  
Gynecology And Obstetrics ◽  
Stage Disease ◽  
Stage 1 ◽  
Atypical Polypoid Adenomyoma

Peritoneal keratin granulomatosis is a rare tumor-like lesion caused by deposition of tumor-produced keratin. It may be associated with endometrial or ovarian endometrioid adenocarcinoma, atypical polypoid adenomyoma of the endometrium, or ruptured mature teratomas of the ovary. We present 2 cases of peritoneal keratin granulomatosis associated with FIGO (International Federation of Gynecology and Obstetrics) stage 1 endometrial adenocarcinoma. This entity can mimic advanced-stage disease clinically and radiologically, as it did in those cases, and constitutes a diagnostic pitfall that pathologists and surgeons must be aware.

Conservative Treatment With Progestin and Pregnancy Outcomes in Endometrial Cancer

2009 ◽  
Vol 19 (6) ◽  
pp. 1068-1073 ◽  
Author(s):  
Ho-Suap Hahn ◽  
Seok-Geun Yoon ◽  
Jae-Shik Hong ◽  
Sung-Ran Hong ◽  
Sei-Jin Park ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Complete Remission ◽  
Conservative Treatment ◽  
Median Time ◽  
Pregnancy Outcomes ◽  
Partial Remission ◽  
Early Stage ◽  
Endometrial Adenocarcinoma ◽  
Persistent Disease ◽  
Dilation And Curettage

Introduction:The purpose of this study was to evaluate the efficacy of conservative treatment with progestin and pregnancy outcomes in women with early-stage endometrial cancer.Methods:We retrospectively analyzed the medical records of 35 patients with endometrial adenocarcinoma, who were treated with progestin from January 1996 to December 2006. Women with early-stage grade 1 endometrioid endometrial adenocarcinoma, who wanted to receive conservative treatment or preserve fertility, were included. All women were treated with medroxyprogesterone acetate or megestrol acetate, with regular dilation and curettage performed. Complete remission (CR) was defined as no evidence of endometrial adenocarcinoma or hyperplasia. Partial remission was diagnosed when the patient developed endometrial hyperplasia, and persistent disease was defined as residual endometrial adenocarcinoma by pathologic confirmation.Results:The median age was 31 years (range, 21-43 years), and the median follow-up period was 39 months (range, 5-108 months). Complete remission was achieved in 22 patients (62.9%), partial remission was achieved in 1 patient (2.9%), and 12 patients (34.3%) had persistent disease. The median time to CR was 9 months (range, 2-12 months). Of the 22 patients with CR, 9 (40.9%) had recurrent disease, and the median time to recurrence was 12 months (range, 8-48 months). Ten (83.3%) of the 12 patients with CR who tried to conceive were successful, and 8 of the 10 pregnancies resulted in live births. There were no congenital anomalies in babies associated with progestin treatment.Conclusions:Conservative treatment with progestin can be considered a good therapeutic option in patients with well-differentiated early-stage endometrioid endometrial adenocarcinoma who wish to preserve their uteri or become pregnant.

Prolonged Conservative Treatment of Endometrial Cancer Patients: More Than 1 Pregnancy Can Be Achieved

2011 ◽  
Vol 21 (1) ◽  
pp. 72-78 ◽  
Author(s):  
Tamar Perri ◽  
Jacob Korach ◽  
Walter H. Gotlieb ◽  
Mario Beiner ◽  
Dror Meirow ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Conservative Treatment ◽  
Early Stage ◽  
Intrauterine Device ◽  
Endometrial Adenocarcinoma ◽  
Tertiary Care ◽  
Young Patients ◽  
High Recurrence Rate ◽  
High Dose ◽  
Endometrioid Adenocarcinoma

Background:Preserving reproductive function in young patients with early endometrial cancer is an accepted concept today. The safety and feasibility of long-term conservative treatment, allowing more than 1 pregnancy, remain to be ascertained.Methods:This study was a retrospective chart review of a 27 women with endometrioid adenocarcinoma of the endometrium, who were treated conservatively at 2 tertiary-care institutions. Treatment comprised oral high-dose progestins with or without a levonorgestrel-releasing intrauterine device. Endometrial biopsy was repeated every 2 to 3 months.Results:Over 7.8 to 412 months (median, 57.4 months), tumors regressed completely in 24 (89%) of 27 patients and partially in 2 patients, with 79% responding within 1 to 17 months. Of the complete responders, 15 (62%) of 24 had a recurrence; 4 underwent hysterectomy, and 11 underwent subsequent progestational treatment. All 11 responded, and 3 subsequently conceived. After 2 to 4 years, 5 patients again had a recurrence, of whom 3 underwent hysterectomy. Overall, 2 patients developed ovarian adenocarcinoma. All patients are currently disease-free. Conception occurred in 14 (51.8%) of 27 patients, in 5 more than once. There were 17 live births, and 2 patients are pregnant.Conclusions:According to our data, prolonged progestational therapy for early-stage endometrial adenocarcinoma, allowing women to conceive, is feasible and apparently does not alter clinical outcome. Patients should be advised of the high recurrence rate and possible concomitant ovarian malignancy.

Oncologic outcomes of conservative treatment of atypical polypoid adenomyoma of the uterus: a two‐center experience

2021 ◽  
Author(s):  
Paolo Casadio ◽  
Antonio Raffone ◽  
Antonio Travaglino ◽  
Diego Raimondo ◽  
Brunella Zizolfi ◽  
...  
Keyword(s):  
Conservative Treatment ◽  
Oncologic Outcomes ◽  
Atypical Polypoid Adenomyoma

Immunocytochemical localization of β1-4 galactosyltransferase in endometrial carcinoma cells

1990 ◽  
Vol 48 (3) ◽  
pp. 944-945
Author(s):  
Ichiro Yamamoto ◽  
Toshiaki Tachibana ◽  
Hiroko Maruyama ◽  
Noriyuki Komatsu ◽  
Hiroyuki Kuramoto ◽  
...  
Keyword(s):  
Endometrial Carcinoma ◽  
Cell Lines ◽  
Endometrial Adenocarcinoma ◽  
Protein A ◽  
Rabbit Antiserum ◽  
Carcinoma Cells ◽  
Affinity Column ◽  
Antibody Technique ◽  
Galactosyl Transferase ◽  
C Terminus

We have paid attention to the alteration of glycosyltransferase in carcinoma cells, because it might be related to the malignancy of the cells. In this connection, localization of β1-4 galactosyl transferase (β1-4 Gal T) in human endometrial carcinoma cells was examined immunocytochemically using two kinds of cell lines, each of which showed different degree of differentiation.An antibody was purified from the rabbit antiserum against the synthetic peptide, IFNRLVFRGMSC (W89) of human β1-4 Gal T coupled with KLH (keyhole limpet hemocyanine) by protein A column and peptide-affinity column chromatography. The anti-W89 serum reacts to the C-terminus of human β 1-4 Gal T and to both membrane-bound and soluble forms of the enzyme. Cell line of well differentiated endometrial adenocarcinoma (I) and that of poorly differentiated endometrial adenocarcinoma (50B) were cultivated respectively in MEM medium containing 15% FCS and 2 mM glutamine for 4 d at 37°C under 5% CO2. The cells were fixed in a mixture of 4% paraformaldehyde and 0.1% glutaraldehyde in 0.1 M Soerensen’s phosphate buffer (pH 7.4) at 4°C for 30 min, washed with PBS, then freezed and thawed. The indirect method of the peroxidase- labeled antibody technique was used for immunocytochemistry of both LM and TEM on the cell lines. The cells were dehydrated in ethanol and embedded in TAAB 812. Ultrathin sections were observed under a TEM, JEM-100S.

Sign in / Sign up

Export Citation Format

Share Document